SiRNA as a conventional drug in the clinic? Challenges and current technologies

Drug Discovery Today: Technologies

Volumn 9, Issue 2, 2012, Pages

  Shim, Min Suk ^a   Wong, Shirley ^b   Kwon, Young Jik ^a,b  

^a University of California at Irvine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; LIPID; LIPOSOME; NANOPARTICLE; PEPTIDE; POLYMER; POLYPEPTIDE; SMALL INTERFERING RNA; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ARTICLE; CANCER THERAPY; CONGENITAL PACHYONYCHIA; DELAYED GRAFT FUNCTION; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG TARGETING; GLAUCOMA; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IN VIVO STUDY; LIVER CANCER; LUNG METASTASIS; MELANOMA CELL; MEMBRANE FUSION; METASTATIC MELANOMA; NONHUMAN; OPTIC NERVE ATROPHY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RESPIRATORY TRACT INFECTION; RETICULOENDOTHELIAL SYSTEM; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; SOLID TUMOR; STATIC ELECTRICITY; SURVIVAL RATE; TECHNOLOGY; VIRUS INFECTION;

EID: 84871542650     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.01.003     Document Type: Review

References (42)

1. Elbashir, S.M. et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498
2. Kim, D.H. and Rossi, J.J. (2007) Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184
3. de Fougerolles, A. et al. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453
4. Whitehead, K.A. et al. (2009) Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138
5. Ni, Z. et al. (2009) Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 223, 401-410
6. Layzer, J.M. et al. (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771
7. Corey, D.R. et al. (2007) Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest. 117, 3615-3622
8. Watts, J.K. et al. (2010) Clinical status of duplex RNA. Bioorg. Med. Chem. 20, 3203-3207
9. Tomanin, R. and Scarpa, M. (2004)Whydo we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction Curr. Gene Ther. 4, 357-372
10. Torchilin, V.P. (2005) Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-160
11. Akeku, M. et al. (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68, 9788-9798
12. Morrissey, D.V. et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007
13. Akinc, A. et al. (2009) Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17, 872-879
14. Lv, H. et al. (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100-109
15. Lian, T. et al. (2001) Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90, 667-680
16. Kim, S.H. et al. (2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129, 107-116
17. Eguchi, A. et al. (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27, 567-571
18. Kwon, E.J. et al. (2008) Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles. Bioconjug. Chem. 19, 920-927
19. De Smedt, S.C. et al. (2000) Cationic polymer based gene delivery systems. Pharm. Res. 17, 113-126
20. Moghimi, S.M. et al. (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol. Ther. 11, 990-995
21. Symonds, P. et al. (2005) Low and high molecular weight poly(L-lysine)s/ poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Lett. 579, 6191-6198
22. Rudzinski, W.E. et al. (2010) Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 399, 1-11
23. Li, S-D. et al. (2008) Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942-946
24. Song, E. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717
25. Davis, M.E. et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070
26. Robbins, M. et al. (2009) siRNA and innate immunity. Oligonucleotides 19, 89-102
27. Samuel-Abraham, S. and Leonard, J.N. (2010) Staying on message: design principles for controlling nonspecific responses to siRNA. FEBS J. 277, 4828-4836
28. Jackson, A. et al. (2006) Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187
29. Khan, A.A. et al. (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 27, 549-555
30. Bramsen, J.B. et al. (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37, 2867-2881
31. Vaish, N. et al. (2011) Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 39, 1823-1832
32. Chen, P.Y. et al. (2008) Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14, 263-274
33. Huesken, D. et al. (2005) Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol. 23, 995-1001
34. Naito, Y. et al. (2004) siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res. 32, W124-W129
35. Andersen, M.Ø. et al. (2008) Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials 29, 506-512
36. Hobel, S. et al. (2008) Polyethylenimine PEI F25-LMW allows the longterm storage of frozen complexes as fully active reagents in siRNAmediated gene targeting and DNA delivery. Eur. J. Pharm. Biopharm. 70, 29-41
37. Kopreski, M.S. et al. (1999) Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res. 5, 1961-1965
38. Keshishian, H. et al. (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6, 2212-2229
39. Krishnamachary, B. et al. (2009) Noninvasive detection of lentiviralmediated choline kinase targeting in a human breast cancer xenograft. Cancer Res. 69, 3464-3471
40. Massoud, T.F. and Gambhir, S.S. (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545-580
41. Bryson, J.M. et al. (2009) Polymer beacons for luminescence and magnetic resonance imaging of DNA delivery. Proc. Natl. Acad. Sci. U. S. A. 106, 16913-16918
42. Bartlett, D.W. et al. (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 104, 15549-15554